Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for childhood stuttering
IRCT20190717044247N1Phase 3Completed
- Sponsor
- Ardabil University of Medical Sciences
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of atomoxetine in childhood-onset fluency disorder (COFD) (2 arms), sponsored by Ardabil University of Medical Sciences. Primary endpoints: Severity of stuttering and SSI-4 score. Started Sep 2019; status: completed.
02
Drugs
atomoxetine
03
Conditions
childhood-onset fluency disorder (COFD)
Beyond the preview
Go deeper on IRCT20190717044247N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190717044247N1.